Skip to content

Insmed

US · INSM #794 by market cap Listed 1970
141.33 -3.13 -2.17%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 143.77 -0.48%
After-hours 142.81 +1.05%
Overnight 144.00 -0.32%
144.4691.88141.332026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on INSM?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -8.1% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 6.4% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bullish
  • Price is above its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days E → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2849 U.S. stocks StockVane covers.

Last computed: 2026-11-21 14:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 79.7% Better than 90%
Operating margin -164.0% Better than 6%
Net margin -210.5% Better than 5%
Return on equity -249.3% Better than 2%
Return on invested capital -88.3% Better than 3%
Momentum B

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 12.4% Better than 92%
6-month return 33.0% Better than 90%
12-month return (ex latest month) -52.2% Better than 3%
Distance below 52-week high 33.6% Better than 37%
Financial Health C+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 3.8x Better than 80%
Debt to assets 25.9% Better than 47%
Interest coverage -15.4x Better than 11%
Analyst View B+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 94.1% Better than 76%
Upside to average target 34.7% Better than 54%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W +16.65%
1M +47.73%
3M +12.99%
6M +30.97%
YTD -18.79%
1Y -29.21%
3Y +474.05%
5Y +363.99%

Key statistics

Price & volume

Prev close
144.46
Open
143.27
Day range
140.99 - 150.00
Avg price
144.02
Volume
6.22M
Turnover
895.27M
Amplitude
6.24%
52-week range
90.39 - 212.75

Valuation

P/E
-22.01
P/E (TTM)
-50.30
P/B
42.70
EPS
-6.42
Net profit
-1.41B
Net assets
726.15M

Share structure

Market cap
31.01B
Float cap
30.80B
Shares out
219.38M
Float shares
217.94M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 42% of range
90.39 212.75

33.6% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-81.98M net over the window

Short interest

Shares short
14.08M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Insmed (INSM)?

Insmed last traded at 141.33. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Insmed's market cap?

About 31.01B.

What is the P/E ratio of Insmed?

The trailing twelve-month P/E is -50.30. The Valuation tab shows it against the stock's own five-year range.

Does Insmed pay a dividend?

Insmed does not currently pay a regular dividend.

Is Insmed a buy according to analysts?

The consensus of 17 analysts is a Buy rating, with an average 12-month price target of 190.31, which implies 34.7% upside from the current price. This is not investment advice.

What is Insmed's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Insmed a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 20:02:34 · For reference only, not investment advice and not tailored to your situation.

Insmed discussion 0 comments

Add a comment